The impact of MET expression on patient outcomes with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT)

被引：0
|
作者：
Albiges, Laurence [1 ,2 ,3 ]
De Velasco, Guillermo [1 ,2 ,3 ]
Gray, Kathryn P. [1 ,2 ,3 ]
Carol, Hallie A. [1 ]
Caella, Marcella [1 ,2 ,3 ]
Mickey, Suzanne S. [1 ,2 ,3 ]
Fay, Andre P. [1 ,2 ,3 ]
Mcdermott, David F. [1 ,2 ,3 ]
Atkins, Michael B. [2 ]
Heng, Daniel Y. [3 ]
Signoretti, Sabina [1 ,2 ,3 ]
Choueiri, Toni K. [1 ]
机构：
[1] Dana Farber Harvard Canc Ctr, Kidney Canc Program, Boston, MA USA
[2] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[3] Tom Baker Canc Clin, Calgary, AB, Canada
来源：
BJU INTERNATIONAL | 2015年 / 116卷
关键词：
MET; mRCC; IHC; VEGF TI;
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1 / 2
页数：2
相关论文
共 50 条
  • [1] Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).
    Bosse, Dominick
    Xie, Wanling
    Wells, Connor
    Lalani, Aly-Khan A.
    Donskov, Frede
    Bent, Alisha
    Sim, Hao-Wen
    Beuselinck, Benoit
    Bamias, Aristotelis
    Porta, Camillo
    Vaishampayan, Ulka N.
    Pal, Sumanta K.
    Agarwal, Neeraj
    Srinivas, Sandy
    Rini, Brian I.
    Alva, Ajjai Shivaram
    Wood, Lori
    Kapoor, Anil
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] The impact of PBRM1 and BAP1 expression on outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).
    Fay, Andre Poisl
    de Velasco, Guillermo
    Gray, Kathryn P.
    Ho, Thai Huu
    Song, Jiaxi
    Kapur, Payal
    Albiges, Laurence
    McDermott, David F.
    Heng, Daniel Yick Chin
    Brugarolas, James
    Choueiri, Toni K.
    Signoretti, Sabina
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [3] Metastatic renal cell carcinoma (mRCC) patients (pts) with sarcomatoid features treated with VEGF-targeted therapy
    Golshayan, A. R.
    George, S.
    Heng, D. Y.
    Elson, P.
    Wood, L.
    Garcia, J. A.
    Aydin, H.
    Zhou, M.
    Bukowski, R. M.
    Rini, B. I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Failure of initial VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC): What next?
    Vickers, M. M.
    Choueiri, T. K.
    Zama, I.
    Cheng, T.
    North, S.
    Knox, J. J.
    Kollmannsberger, C.
    McDermott, D. F.
    Rini, B. I.
    Heng, D. Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC).
    de Velasco, Guillermo
    Xie, Wanling
    Donskov, Frede
    Albiges, Laurence
    Beuselinck, Benoit
    Srinivas, Sandhya
    Agarwal, Neeraj
    Lee, Jae-Lyun
    Brugarolas, James
    Wood, Lori
    Kollmannsberger, Christian K.
    Rha, Sun Young
    North, Scott A.
    Kanesvaran, Ravindran
    Rini, Brian I.
    Broom, Reuben James
    Yamamoto, Haru
    Kaymakcalan, Marina Dusevic
    Heng, Daniel Yick Chin
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [6] Cessation of VEGF-targeted therapy in patients with metastatic renal cell carcinoma (mRCC): Feasibility and clinical outcome
    Sadeghi, S.
    Albiges, L.
    Wood, L. S.
    Black, S. L.
    Gilligan, T. D.
    Dreicer, R.
    Garcia, J. A.
    Escudier, B. J.
    Rini, B. I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [7] Temsirolimus (TEM) in metastatic renal cell carcinoma (mRCC): Safety and efficacy in patients (pts) previously treated with VEGF-targeted therapy
    Wood, L.
    Bukowski, R. M.
    Dreicer, R.
    Elson, P.
    Garcia, J. A.
    Gilligan, T.
    Mekhail, T.
    Rini, B. I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT).
    Ernst, Matthew Scott
    Abou Alaiwi, Sarah
    Dizman, Nazli
    Labaki, Chris
    Nuzzo, Pier Vitale
    Adib, Elio
    Schmidt, Andrew Lachlan
    Meza, Luis A.
    Gan, Chun Loo
    Wells, J. Connor
    Bakouny, Ziad
    Pal, Sumanta K.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    Dudani, Shaan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Predictive and Prognostic Clinicopathologic Factors of Metastatic Renal Cell Carcinoma Treated with VEGF-Targeted Therapy
    Park, J. Y.
    Lee, J-L
    Ro, J. Y.
    Cho, Y. M.
    [J]. LABORATORY INVESTIGATION, 2013, 93 : 239A - 239A
  • [10] Predictive and Prognostic Clinicopathologic Factors of Metastatic Renal Cell Carcinoma Treated with VEGF-Targeted Therapy
    Park, J. Y.
    Lee, J-L
    Ro, J. Y.
    Cho, Y. M.
    [J]. MODERN PATHOLOGY, 2013, 26 : 239A - 239A
12345